1887

Abstract

A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime–boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18738-0
2003-02-01
2020-11-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/2/vir840361.html?itemId=/content/journal/jgv/10.1099/vir.0.18738-0&mimeType=html&fmt=ahah

References

  1. Allen T. M., Vogel T. U., Fuller D. H.. 11 other authors 2000; Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol164:4968–4978
    [Google Scholar]
  2. Altman J. D., Moss P. A. H., Goulder P. J., Barouch D. H., McHeyzer-Williams M. G., Bell J. I., McMichael A. J., Davis M. M.. 1996; Phenotypic analysis of antigen-specific T lymphocytes. Science274:94–96
    [Google Scholar]
  3. Amara R. R., Villinger F., Altman J. D.. 19 other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science292:69–74
    [Google Scholar]
  4. Atkins G. J., Sheahan B. J., Liljeström P.. 1999; The molecular pathogenesis of Semliki Forest virus: a model virus made useful?. J Gen Virol80:2287–2297
    [Google Scholar]
  5. Berglund P., Quesada-Rolander M., Putkonen P., Biberfeld G., Thorstensson R., Liljeström P.. 1997; Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses13:1487–1495
    [Google Scholar]
  6. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B.. 1994; Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol68:6103–6110
    [Google Scholar]
  7. Borrow P., Lewicki H., Wei X.. 8 other authors 1997; Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med3:205–211
    [Google Scholar]
  8. Fleeton M. N., Sheahan B. J., Gould E. A., Atkins G. J., Liljeström P.. 1999; Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol80:1189–1198
    [Google Scholar]
  9. Fleeton M. N., Liljeström P., Sheahan B. J., Atkins G. J.. 2000; Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol81:749–758
    [Google Scholar]
  10. Garboczi D. N., Hung D. T., Wiley D. C.. 1992; HLA-A2–peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A89:3429–3433
    [Google Scholar]
  11. Goulder P. J. R., Phillips R. E., Colbert R. A.. 9 other authors 1997; Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med3:212–217
    [Google Scholar]
  12. Haas G., Plikat U., Debre P.. 10 other authors 1996; Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo . J Immunol157:4212–4221
    [Google Scholar]
  13. Hanke T.. 2001; Prospect of a prophylactic vaccine for HIV. Br Med Bull58:205–218
    [Google Scholar]
  14. Hanke T., McMichael A. J.. 2000; Design and construction of an experimental HIV-1 vaccine for a year – 2000 clinical trial in Kenya. Nat Med6:951–955
    [Google Scholar]
  15. Hanke T., Blanchard T. J., Schneider J., Hannan C. M., Becker M., Gilbert S. C., Hill A. V. S., Smith G. L., McMichael A.. 1998; Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine16:439–445
    [Google Scholar]
  16. Hanke T., Samuel R. V., Blanchard T. J.. 11 other authors 1999; Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol73:7524–7532
    [Google Scholar]
  17. Heeney J. L., Koopman G., Rosenwirth B.. 12 other authors 2000; A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J Med Primatol29:268–273
    [Google Scholar]
  18. Jin X., Bauer D. E., Tuttleton S. E.. 11 other authors 1999; Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med189:991–998
    [Google Scholar]
  19. Kent S. J., Woodward A., Zhao A.. 1997; Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with the control of acute HIV-1 infection in macaques. J Infect Dis176:1188–1197
    [Google Scholar]
  20. Kent S. J., Zhao A., Best S. J., Chandler J. D., Boyle D. B., Ramshaw I. A.. 1998; Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol72:10180–10188
    [Google Scholar]
  21. Koenig S., Conley A. J., Brewah Y. A.. other authors 1995; Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med1:330–336
    [Google Scholar]
  22. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., McLoed G., Borkowsky W., Farthing C., Ho D. D.. 1994; Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol68:4650–4655
    [Google Scholar]
  23. Kwong P. D., Wyatt R., Robinson J., Sweet R. W., Sodroski J., Hendrickson W. A.. 1998; Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature393:638–659
    [Google Scholar]
  24. Liljeström P., Garoff H.. 1994; Expression of proteins using Semliki Forest virus vectors. In Current Protocols in Molecular Biology pp 1092–1098 Edited by Ausubel A. F.. New York: Greene Publishing Associates and Wiley Interscience;
    [Google Scholar]
  25. McMichael A. J., Hanke T.. 2002; The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. Nat Rev Immunol2:283–291
    [Google Scholar]
  26. Mossman S. P., Bex F., Berglund P.. 11 other authors 1996; Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol70:1953–1960
    [Google Scholar]
  27. Neilson J. R., John G. C., Carr J. K.. 13 other authors 1999; Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol73:4393–4403
    [Google Scholar]
  28. Nilsson C., Makitalo B., Berglund P.. 8 other authors 2001; Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine19:3526–3536
    [Google Scholar]
  29. Osterhaus A. D., van Baalen C. A., Gruters R. A.. 9 other authors 1999; Vaccination with Rev and Tat against AIDS. Vaccine17:2713–2714
    [Google Scholar]
  30. Phillips R. E., Rowland-Jones S., Nixon D. F.. 8 other authors 1991; Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature354:453–459
    [Google Scholar]
  31. Price D. A., Goulder P. J., Klenerman P., Sewell A. K., Easterbrook P. J., Troop M., Bangham C. R., Phillips R. E.. 1997; Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A94:1890–1895
    [Google Scholar]
  32. Price D. A., Sewell A. K., Dong T., Tan R., Goulder P. J., Rowland-Jones S. L., Phillips R. E.. 1998; Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol8:355–358
    [Google Scholar]
  33. Robinson H. L., Montefiori D. C., Johnson R. P.. 14 other authors 1999; Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med5:526–534
    [Google Scholar]
  34. Rowland-Jones S. L., McMichael A.. 1995; Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Curr Opin Immunol7:448–455
    [Google Scholar]
  35. Schmitz J. E., Kuroda M. J., Santra S.. 13 other authors 1999; Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science283:857–860
    [Google Scholar]
  36. Schneider J., Gilbert S. C., Blanchard T. J.. 7 other authors 1998; Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med4:397–402
    [Google Scholar]
  37. Smerdou C., Liljeström P.. 1999a; Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol73:1092–1098
    [Google Scholar]
  38. Smerdou C., Liljeström P.. 1999b; Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther1:244–251
    [Google Scholar]
  39. Smerdou C., Liljeström P.. 2000; Alphavirus vectors: from protein production to gene therapy. Gene Ther Reg1:33–63
    [Google Scholar]
  40. Takahashi H., Cohen J., Hosmalin A.. 7 other authors 1988; An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A85:3105–3109
    [Google Scholar]
  41. Wagner L., Yang O. O., Garcia-Zepeda E. A., Ge Y., Kalams S. A., Walker B. D., Pasternack M. S., Luster A. D.. 1998; Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature391:908–911
    [Google Scholar]
  42. Wilson C. C., Brown R. C., Korber B. T.. 13 other authors 1999; Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant. J Virol73:3975–3985
    [Google Scholar]
  43. Wilson J. D., Ogg G. S., Allen R. L.. 8 other authors 2000; Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS14:225–233
    [Google Scholar]
  44. Wolinsky S. M., Korber B. T., Neumann A. U.. 7 other authors 1996; Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science272:537–542
    [Google Scholar]
  45. Wyatt R., Kwong P. D., Desjardins E., Sweet R. W., Robinson J., Hendrickson W. A., Sodroski J. G.. 1998; The antigenic structure of the HIV gp120 envelope glycoprotein. Nature393:705–711
    [Google Scholar]
  46. Yang O. O., Kalams S. A., Trocha A., Cao H., Luster A., Johnson R. P., Walker B. D.. 1997; Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol71:3120–3128
    [Google Scholar]
  47. Zhang C., Cui Y., Houston S., Chang L. J.. 1996; Protective immunity to HIV-1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals. Proc Natl Acad Sci U S A93:14720–14725
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18738-0
Loading
/content/journal/jgv/10.1099/vir.0.18738-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error